BACKGROUND: Inflammatory factors and low HDL-C relate to CHD risk, but whether inflammation attenuates any protective association of high HDL-C is unknown. OBJECTIVE: Investigate inflammatory markers' individual and collective impact on the association of HDL-C with incident coronary heart disease (CHD). METHODS: In 3888 older adults without known cardiovascular disease (CVD), we examined if the inflammatory markers C-reactive protein (CRP), interleukin-6 (IL-6), and lipoprotein-associated phospholipase A2 (Lp-PLA₂) modify the relation of HDL-C with CHD. HDL-C, CRP, IL-6, and Lp-PLA₂ values were grouped as using gender-specific tertiles. Also, an inflammation index of z-score sums for CRP, IL-6, and Lp-PLA₂ was categorized into tertiles. We calculated CHD incidence for each HDL-C/inflammation group and performed Cox regression, adjusted for standard CVD risk factors and triglycerides to examine the relationship of combined HDL-C-inflammation groups with incident events. RESULTS: CHD incidence (per 1000 person years) was higher for higher levels of CRP, IL-6, and the index, and lower for higher levels of HDL-C. Compared to high HDL-C/low-inflammation categories (referent), adjusted HRs for incident CHD were increased for those with high HDL-C and high CRP (HR = 1.50, p < 0.01) or highest IL-6 tertile (HR = 1.40, p < 0.05), but not with highest Lp-PLA₂ tertile. Higher CHD incidence was similarly seen for those with intermediate or low HDL-C accompanied by high CRP, high IL-6, or a high inflammatory index. CONCLUSION: The protective relation of high HDL-C for incident CHD appears to be attenuated by greater inflammation.
BACKGROUND: Inflammatory factors and low HDL-C relate to CHD risk, but whether inflammation attenuates any protective association of high HDL-C is unknown. OBJECTIVE: Investigate inflammatory markers' individual and collective impact on the association of HDL-C with incident coronary heart disease (CHD). METHODS: In 3888 older adults without known cardiovascular disease (CVD), we examined if the inflammatory markers C-reactive protein (CRP), interleukin-6 (IL-6), and lipoprotein-associated phospholipase A2 (Lp-PLA₂) modify the relation of HDL-C with CHD. HDL-C, CRP, IL-6, and Lp-PLA₂ values were grouped as using gender-specific tertiles. Also, an inflammation index of z-score sums for CRP, IL-6, and Lp-PLA₂ was categorized into tertiles. We calculated CHD incidence for each HDL-C/inflammation group and performed Cox regression, adjusted for standard CVD risk factors and triglycerides to examine the relationship of combined HDL-C-inflammation groups with incident events. RESULTS: CHD incidence (per 1000 person years) was higher for higher levels of CRP, IL-6, and the index, and lower for higher levels of HDL-C. Compared to high HDL-C/low-inflammation categories (referent), adjusted HRs for incident CHD were increased for those with high HDL-C and high CRP (HR = 1.50, p < 0.01) or highest IL-6 tertile (HR = 1.40, p < 0.05), but not with highest Lp-PLA₂ tertile. Higher CHD incidence was similarly seen for those with intermediate or low HDL-C accompanied by high CRP, high IL-6, or a high inflammatory index. CONCLUSION: The protective relation of high HDL-C for incident CHD appears to be attenuated by greater inflammation.
Authors: G Theilmeier; B De Geest; P P Van Veldhoven; D Stengel; C Michiels; M Lox; M Landeloos; M J Chapman; E Ninio; D Collen; B Himpens; P Holvoet Journal: FASEB J Date: 2000-10 Impact factor: 5.191
Authors: M Navab; S Y Hama; C J Cooke; G M Anantharamaiah; M Chaddha; L Jin; G Subbanagounder; K F Faull; S T Reddy; N E Miller; A M Fogelman Journal: J Lipid Res Date: 2000-09 Impact factor: 5.922
Authors: William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub Journal: N Engl J Med Date: 2011-11-15 Impact factor: 91.245
Authors: C J Packard; D S O'Reilly; M J Caslake; A D McMahon; I Ford; J Cooney; C H Macphee; K E Suckling; M Krishna; F E Wilkinson; A Rumley; G D Lowe Journal: N Engl J Med Date: 2000-10-19 Impact factor: 91.245
Authors: Vasilis Tsimihodimos; Sonia-Athena P Karabina; Afroditi P Tambaki; Eleni Bairaktari; John A Goudevenos; M John Chapman; Moses Elisaf; Alexandros D Tselepis Journal: Arterioscler Thromb Vasc Biol Date: 2002-02-01 Impact factor: 8.311
Authors: Enrica Golia; Giuseppe Limongelli; Francesco Natale; Fabio Fimiani; Valeria Maddaloni; Pina Elvira Russo; Lucia Riegler; Renatomaria Bianchi; Mario Crisci; Gaetano Di Palma; Paolo Golino; Maria Giovanna Russo; Raffaele Calabrò; Paolo Calabrò Journal: World J Cardiol Date: 2014-07-26
Authors: Anna E Bortnick; Traci M Bartz; Joachim H Ix; Michel Chonchol; Alexander Reiner; Mary Cushman; David Owens; Eddy Barasch; David S Siscovick; John S Gottdiener; Jorge R Kizer Journal: Heart Date: 2016-07-13 Impact factor: 5.994
Authors: Robert T Mankowski; Mylene Aubertin-Leheudre; Daniel P Beavers; Anda Botoseneanu; Thomas W Buford; Timothy Church; Nancy W Glynn; Abby C King; Christine Liu; Todd M Manini; Anthony P Marsh; Mary McDermott; Joe R Nocera; Marco Pahor; Elsa S Strotmeyer; Stephen D Anton Journal: Exp Gerontol Date: 2015-06-28 Impact factor: 4.032
Authors: Meng Wang; James Corsetti; Scott McNitt; David Q Rich; Charles E Sparks; Arthur J Moss; Wojciech Zareba Journal: J Clin Lipidol Date: 2016-12-28 Impact factor: 4.766
Authors: C-Y Oliver Chen; Monika Holbrook; Mai-Ann Duess; Mustali M Dohadwala; Naomi M Hamburg; Bela F Asztalos; Paul E Milbury; Jeffrey B Blumberg; Joseph A Vita Journal: Nutr J Date: 2015-06-17 Impact factor: 3.271
Authors: Giuseppina T Russo; Annalisa Giandalia; Elisabetta L Romeo; Angela Alibrandi; Katalin V Horvath; Bela F Asztalos; Domenico Cucinotta Journal: Int J Endocrinol Date: 2014-09-02 Impact factor: 3.257